Skip to Main Content

Incyte (INCY) agreed to pay $12.6 million to settle allegations that donations amounted to kickbacks paid to Medicare patients as a way to cover their out-of-pocket costs, the latest in a growing list of drug makers to reach such a deal with the U.S. government.

At issue is a federal law known as the Anti-Kickback Statute, which prohibits pharmaceutical companies from offering or paying — whether directly or indirectly — money or anything else of value to induce Medicare or other federal programs to purchase their drugs. The Department of Justice has previously alleged some charities made it possible for drug companies to evade the law.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.